Biotech Values

[drbio45]

Merrimack Pharmaceuticals.

I am invested in the company. the raise of 65 million dollars was at 4.50 a share which doesn't mean anything since the company is private. It just means they did it at a higher price than I paid.

The post money valuation of the company is 270 million which is extremly high for a company that doesn't even have phase 2 efficacy data out yet. The science is very sound and that is why these new investors were willing to put this money into the company.

If they get good data they will probably get a blockbuster deal done because the drug shouldn't have any side effects.

In fact people with excess alphafetoprotein tend to be healthy and live longer, unless they have liver cancer